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Background: HCV disproportionately affects marginalized communities such as homeless populations and
people who inject drugs (PWID), posing a challenge to traditional health services. The HepFriend initiative in
London is a model of care utilizing HCV outreach screening and peer support to link vulnerable individuals to
HCV treatment in secondary care.
Objectives: To assess the cost-effectiveness of the HepFriend initiative from a healthcare provider perspective,
compared with standard-of-care pathways (consisting of testing in primary care and other static locations,
including drug treatment centres, and linkage to secondary care).
Methods: Cost-effectiveness analysis using a dynamic HCV transmission and disease progression model among
PWID and those who have ceased injecting, including housing status and drug treatment service contact. The
model was parameterized using London-specific surveillance and survey data, and primary intervention cost
and effectiveness data (September 2015 to June 2018). Out of 461 individuals screened, 197 were identified as
HCV RNA positive, 180 attended secondary care and 89 have commenced treatment to date. The incremental
cost-effectiveness ratio (ICER) was determined using a 50 year time horizon.
Results: For a willingness-to-pay threshold of £20000 per QALY gained, the HepFriend initiative is cost-effective,
with a mean ICER of £9408/QALY, and would become cost saving at 27% (£10525 per treatment) of the current
drug list price. Results are robust to variations in intervention costs and model assumptions, and if treatment
rates are doubled the intervention becomes more cost-effective (£8853/QALY).
Conclusions: New models of care that undertake active case-finding with enhanced peer support to improve
testing and treatment uptake amongst marginalized and vulnerable groups could be highly cost-effective and
possibly cost saving.
Introduction
HCV is a bloodborne virus that results in significant morbidity.
Globally, 71 million individuals are living with chronic HCV infection
and 700000 people die from HCV-related liver disease every year.1
In Europe, the number of chronic infections was recently esti-
mated at 14 million,1 with 210000 in the UK.2,3 Early disease is
asymptomatic and therefore individuals with chronic HCV present
for care at late stages of the disease, which have lower survival
rates due to complications such as hepatocellular carcinoma and
decompensated cirrhosis.4
In 2016, the WHO called for an end to the public health threat of
viral hepatitis by 2030, by reducing new infections by 90% and
mortality by 65%. New direct-acting antivirals (DAAs) are highly cura-
tive [sustained viral response (SVR) >95%], short duration
(8–12 weeks) and have few side effects. Since their introduction, HCV-
related mortality has decreased in the UK.4 Additionally, curing HCV in
people who inject drugs (PWID) could prevent further HCV transmis-
sion,5,6 making early treatment of PWID a priority that could be highly
cost-effective.7
HCV disproportionately affects vulnerable and marginalized
communities: not just PWID, but also prisoners and the homeless.
Among these groups, travel for accessing treatment can be
expensive and impractical, whilst mistrust in the health system
and difficulty in navigating hospital-based care pathways are
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significant barriers to engaging in care.8,9 Emerging evidence
focused on TB (which affects similar groups) suggests that com-
munity- and primary care-based models of treatment are effective
in locating and engaging vulnerable groups through bringing
health services to them that are responsive to their needs.10,11
Whilst there has been increased HCV testing in community settings
in the UK, and an increase in community treatment clinics, linkage
to care remains an issue. Indeed, a recent trial of a peer-based
intervention found that even with peer support only 36.5% of their
‘hard-to-reach’ cohort engaged with treatment services.12
HepCare is a new model of care that links primary, secondary,
outreach and community care and treatment for at-risk popula-
tions in the EU. In London, the University College London Hospital
(UCLH) NHS Trust and homeless charity Groundswell are collabo-
rating to deliver two components of HepCare: HepCheck and
HepFriend. In this setting, HepCheck involves active case-finding
through outreach activities to identify homeless individuals with
HCV infection. HepFriend then builds on HepCheck by incorporating
peer support to help individuals navigate the testing and treat-
ment pathway from outreach to secondary care. Henceforth the
intervention will be described as HepFriend.
There are a few cost-effectiveness analyses of HCV case-
finding interventions,13–15 but none has included street-based out-
reach. This study evaluates the cost-effectiveness of the
HepFriend intervention in London in addition to the standard-of-
care pathway, compared with the standard-of-care pathway only.
Methods
Description of comparators
Standard-of-care pathway
The comparator testing and care pathway for vulnerable individuals in this
setting would be diagnosis at a GP or drug treatment centre with either a
nurse or GP undertaking dried blood spot (DBS) laboratory testing, with
reflex RNA testing being done if the sample is antibody positive. Referral to
hospital for specialist care and assessment for HCV treatment would
then occur if the sample was RNA positive. There would also be multiple
appointments for on-treatment monitoring with a specialist nurse and a
post-treatment appointment to determine treatment success (sustained
virological response, SVR).
HepFriend intervention pathway
The HepFriend Team, comprising two nurses and a peer worker from
Groundswell (a homeless charity), undertook active case-finding for HCV via
outreach activities, visiting homeless hostels, drug treatment centres and
street locations (Figure S1, available as Supplementary data at JAC Online).
The team visited locations either by public transport or with the specialized
Find & Treat mobile screening unit. The team spent time with potential
patients, building relationships, raising awareness of HCV, and then offering
the opportunity of an HCV assessment. If patients accepted, risk factors were
assessed and an HCV antibody (Ab) point-of-care test (POCT) was performed.
If positive, then a FibroScan and DBS test were performed. If the patient
had advanced fibrosis but was not RNA positive, then they were referred
to their GP. Conversely, if they were RNA positive, then the patient was
followed up through their mobile phone, key worker, visiting their hostel,
visiting the pharmacy where they receive prescriptions or visiting street
locations to find them. Once located, the team encouraged the patient
to make a referral appointment at the hospital, which was done quickly
to the minimize loss to follow-up. If necessary, the peer worker then
accompanied the patient to hospital visits and would observe them tak-
ing their treatment, directly, over the phone or by video.
Costing analysis
The analysis was undertaken from a UK NHS and Personal and Social
Services perspective, with all costs in 2018 British pounds (£1 = $1.30 USD).
Costs from previous years were inflated to 2018 costs using the Health and
Community Hospital Service pay and prices index.
Healthcare costs relating to HCV disease stages were taken from previ-
ous economic analyses (Table S2).7,16 For the standard of care, screening
costs in primary care and drug treatment centres were taken from literature
(Table 1).17,18 Costs relating to the treatment pathway in hospitals using
DAAs were based on the treatment protocol for a London hospital with unit
costs obtained from the NHS reference cost database (Table 1 and Table S4).
Costs for opioid substitution therapy (OST) prescriptions only included drug
costs.19 DAA treatments were assumed to cost the full list price.
Financial and economic costs for HepFriend for 2017/18 were collected
from a provider perspective and classified as capital or recurrent. Data were
gathered from UCLH and Groundswell’s financial records, salary grades and
Table 1. Costs for testing, engagement and treatment in standard-of-care comparator arm
Step in pathway of care Baseline cost Source
Costs for each test (includes staff time and test costs)
Ab negative £46.26 (staff cost)! £7.61 (Ab test cost) 17
Ab positive £46.26! £7.61! £66.00 (RNA test cost)
previous known SVR (Ab positive) £46.26! £66.00
Costs for engagement (includes staff referral costs and preliminary blood tests and FibroScan at the hospital)
from diagnosed £334.96 (at hospital)! £77.10 (referral cost) 17 and personal communication, G. Foster (HCV
Clinical Lead for England)
from lost to follow-up 0 (no engagement from lost to follow up at baseline) assumption
Costs for each treatment
treatment monitoring £395.82 personal communication, G. Foster (HCV Clinical
Lead for England); see Supplementary data
for details
weekly drug cost £3248.00 43
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through staff interviews to record spending on capital buildings, vehicles,
training and equipment costs, recurrent staff, supplies, and training costs.
Both UCLH and Groundswell had already calculated the overheads used by
HepCare in the development of funding applications. These figures were
varied in sensitivity analyses.
Costs were then allocated to the designated ‘activities’ of HepFriend:
management and administration, research, outreach sessions and mobile
van outreach sessions, POCTs, RNA tests, FibroScans, follow-up of RNA posi-
tive or RNA negative clients, and peer support for different hospital visits. A
bottom-up, ingredients approach was used to estimate costs for each per-
son tested, based on recorded resource use including staff time (nurses,
peer workers), van use, and diagnostic and clinical tests. Van mileage was
not available, so the number of sessions that the mobile screening unit was
used for HepFriend as a proportion of all sessions undertaken was used to
allocate its costs to the intervention. Top-down analysis apportioned costs
associated with administration and management time to activities based
on measures such as staff time.
Mathematical model description
The cost-effectiveness analysis was conducted using a dynamic model
that incorporates HCV transmission among PWID and disease progression
in PWID and ex-injectors. The model is a deterministic compartmental
model (see Supplementary data), stratified by infection, disease progres-
sion (Figure S2), treatment stages (Figure 1), injecting status (injecting or no
longer injecting), whether on OST, and homelessness status (rough sleep-
ing or in a hostel within the last year) (Figure 2).
Briefly, an individual enters the model as susceptible, not homeless
or on OST and can become infected at a rate dependent on the
prevalence of chronic infection in the population. New infections either
spontaneously clear and move to the exposed category or develop
chronic infection. Chronically infected individuals can be diagnosed, and
then either enter the treatment pathway or are lost to follow-up (with
disease progressing over time). Engagement in the treatment pathway
includes all appointments between diagnosis and initiating treatment
(FibroScan, liver function tests etc.). Only those engaged in the treat-
ment pathway can start treatment. Upon successful treatment, individ-
uals enter a susceptible SVR state with equivalent disease progression.
Re-infection can occur if they have not ceased injecting. Those who fail
treatment are re-treated.
Movement between homeless and OST categories occurs at specific
rates. Upon cessation of injecting, individuals become ex-injectors but may
remain homeless. PWID experience drug-related mortality and the mortal-
ity of ex-injectors is dependent on their homeless status.
Model parameterization and calibration for current
standard-of-care comparator
To model the cost-effectiveness of the HepFriend intervention, the first step
is to parameterize the model for the current standard-of-care pathway,
and following that to incorporate the effects of the intervention. The model
was parameterized and calibrated to a London-specific epidemiological
scenario with an estimated 41% HCV chronic prevalence among a PWID
population of about 16700.4,20,21 It was assumed that 78% of PWID are on
OST and 33% have been homeless in the last year.22 Data suggest OST
coverage, HCV prevalence and homelessness have been stable over recent
years, and so this was assumed in the model calibration.4,22 Based on a re-
cent Cochrane review, currently being on OST was assumed to reduce the
risk of HCV transmission by 59%,23 whereas recent homelessness increases
the risk of HCV transmission 2.1-fold.24 Other demographic and epidemio-
logical parameters are shown in Table 2.
We assumed 57% of chronically infected PWID are diagnosed at the
start of the HepFriend intervention,4 with current OST assumed to increase
the annual likelihood of being tested by 22%.25 The testing rate amongst
those not on OST was estimated though model calibration. Data collected
during the HepFriend study estimated that 12% of previously diagnosed
individuals had engaged with the treatment pathway, which was used to
estimate an engagement rate. The subsequent standard-of-care treat-
ment rate (28% within year of engagement) came from baseline data from
a recent UK study.18 Because no SVR data were available from HepFriend,
an SVR rate of 93% was assumed for sofosbuvir and velpatasvir based on
data from the SIMPLIFY trial, which treated people with recent injecting
drug use.26
All model parameters had uncertainty distributions associated with
them (Table 2). For the model calibration, 1000 parameter sets were
sampled from these distributions. For each parameter set, the model was
calibrated to sampled data on the HCV chronic prevalence amongst current
PWID, OST coverage and proportion diagnosed (prior to intervention),
through varying the infection rate, OST recruitment rate and testing rate.
Further details on the calibration process can be found in the supporting
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Figure 1. Model structure of the HCV infection and treatment processes.
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information. Each calibrated model fit was used to simulate the standard-
of-care and intervention scenarios.
Intervention scenario parameterization
We modelled the intervention scenario for three years (2016–18), during
which the number of people diagnosed or identified (200), engaged with
the treatment pathway (198) and commencing treatment (99) was
increased based on results from the HepFriend intervention (Figure 3).
HepFriend data on screening dates were used to determine when people
were diagnosed and engaged with the treatment pathway. Data collected
at screening were used to categorize whether the screened and treated
individuals were on OST, homeless or currently injecting, and their current
stage of disease (determined through fibrosis score;27 see Supplementary
data for details).
Utility values
Parameter estimates for health utilities and HCV disease progression rates
were taken from the literature (Table S1).7,28–31 Early disease progression
parameters, from Metavir state F0 through to F4, use data from a meta-
analysis of studies monitoring disease progression in PWID to incorporate
the higher disease progression seen in this population compared with the
general population.28,31 The reduced disease progression rates once SVR is
attained came from studies of IFN-based therapy as recent evidence
suggests DAA-induced SVR results in changes in disease progression similar
to those for IFN-induced SVR.32 We assumed that susceptible homeless
PWID have the same utility as other PWID (mean 0.73).33 PWID that cease
injecting are assumed to have a higher health utility than active PWID
(mean 0.85 versus 0.73), whereas homeless individuals remain with a lower
health utility (mean 0.76).34 Those who become infected then have health
utilities related to their disease stage multiplied by their uninfected health
utility. Costs and health utilities were attached to each model state and
discounted at 3.5% per year.35 Health utilities are summed for the popula-
tion over the time horizon to give quality-adjusted life years (QALYs).
Cost effectiveness analysis
The analysis used a 50 year time horizon (to 2066, 3 years of intervention
and 47 years of follow-up) to capture long-term effects of HCV infection as
well as population prevention benefits associated with treating HCV. The in-
cremental cost-effectiveness ratio (ICER) was calculated as the difference
in costs divided by the difference in QALYs between the HepFriend interven-
tion and standard-of-care scenarios. Cost-effectiveness was determined
using the UK willingness-to-pay (WTP) threshold of £20000 per QALY
saved.35 The numbers of infections and disease-related deaths averted
by the intervention were also calculated.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (PSA), varying demographic and epidemic
parameters, healthcare costs and health utilities randomly across specified
distributions, was used to form a joint distribution of the differences in cost
and QALYs for the intervention. The mean ICER was calculated using the
PSA outputs. ANCOVA was conducted to determine which model parame-
ter’s uncertainty contributed most to the variability in the incremental
costs, QALYs and infections averted by the intervention.36
Sensitivity analyses
Two sensitivity analyses were conducted to test the effect of model
assumptions on our cost-effectiveness projections. Firstly, we assumed all
individuals identified by the intervention were newly diagnosed, rather
than some being diagnosed previously and lost to follow-up. Secondly, we
assumed all individuals in the model were current injectors, rather than ei-
ther injectors or ex-injectors. Sensitivity analyses also tested the effect of
assumptions made in the costing analysis. These included doubling or tri-
pling overhead costs, due to the difficulty in estimating the overhead costs
for this kind of intervention. Intervention start-up costs were annualized
over 5 years in the base-case analysis, and we tested annualizing over 3
and 7 years in sensitivity analyses. We also tested how our projections
would vary if we assumed all screening sessions used the Find & Treat
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Figure 2. Model structure for categories of PWID and homeless individuals.
Ward et al.
v8
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/Supplem
ent_5/v5/5645641 by U
niversity of Bristol Library user on 04 D
ecem
ber 2019
Table 2. Model parameters and calibration data common to comparator and intervention
Parameter Value Source
HCV transmission
chronic HCV prevalence in 2016 41% (36%–46%) Adjusted from 55% seroprevalence (50%–60%)44 assum-
ing some have spontaneously cleared their infection.
risk ratio for HCV transmission and acquisition
while on OST
0.40 (0.22–0.75) 23
risk ratio for HCV transmission and acquisition
while homeless
2.10 (1.41–3.24) 24
HCV transmission rate when not homeless or
on OST
varied to give HCV prevalence
in 2016
Assume HCV prevalence is stable in the population
of PWID.
Testing
percentage of current injectors diagnosed for
standard of care
57% (52%–62%) 44
factor increase in testing rate in OST compart-
ment compared with not being on OST
1.22 (1.10–1.35) Data analysed from needle exchange surveillance
initiative in Scotland.25
testing rate in non-OST and ex-injector
compartments
varied to give proportion diagnosed
shown above (57%)
Assume proportion of injectors diagnosed is stable.
Engagement and treatment
engagement rate from diagnosis for standard
of care pathway in all compartments
0.13 (0.09–0.18) per year Proportion 0.12 (0.08–0.17) engaged in treatment before
intervention (data from HepFriend study initial inter-
views). Assume this is all in the last year to get yearly
rate.
treatment rate from engaged per year for
standard-of-care pathway in all
compartments
0.34 (0.17–0.59) Treatment rate among engaged patients from recent UK
HepCATT study.18
percentage of treatments that attain SVR 93% (88%–97%) SIMPLIFY trial among PWID.26
transition rate from treatment to SVR per year 1/(12/52) Treatment assumed to last 12 weeks.26
Demographics
population size of injectors 16700 (12525–20875) Operational Delivery Network Profile Tool developed by
PHE.21
cessation rate of injectors 0.088 (0.053–0.125) per year Assume mean duration 11 (8–15) years in UK.45 Assumes
OST does not affect cessation rate.
rate of initiation of injecting used to fit population size
estimates
Assume stable population size.
percentage of injectors that are homeless 33% (26%–40%) Unlinked anonymous monitoring survey data for
London.22
transition rate (not homeless to homeless) varied to give the sampled
proportion of injectors that
are homeless
Assume stable proportion of homeless individuals in
the population.
transition rate (homeless to not homeless) 1.16 (0.83–1.64) per year Scottish cohort study found 78/145 homeless PWID were
no longer homeless after 8 months.46 Transition
probability sampled from b distribution (a=78, b=67)
and converted into yearly rate.
percentage of PWID on OST 78% (73%–83%) Unlinked anonymous monitoring survey data for
London.22
transition rate (on OST to not on OST) 1.48 (1.00–2.98) per year Duration on OST was 8 months (4–12 months) in a cohort
of PWID in UK.47
transition rate (not on OST to on OST) varied to give proportion of PWID
on OST
Assume proportion of PWID on OST is stable.
current injector and homeless mortality same as drug-related death rate Meta-analysis of mortality in homeless individuals, pris-
oners and individuals with substance use disorders
gave similar mortality ratios for individuals with drug
use disorders and individuals who are homeless.48
Continued
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Table 2. Continued
Parameter Value Source
ex-injector death rate 0.023 (0017–0.032) per year 1/(life expectancy–age at initiation of injecting–injecting
duration).
ex-injector homeless death rate 0.043 (0.026–0.089) per year Calculated as for ex-injector death rate with 19 (16–22)
years less life expectancy than those who are not cur-
rently homeless.38
Previously
diagnosed 27
Screened 1092016
2017
2018
50 19 18
45
65
39
116
509936
20 16
4551
71
91
Tested 50
POCT, 29 RNA
27 27
Engaged 45
Previously
diagnosed 71
New
diagnoses 51
Treatment 39Engaged 155
Treatment 50Engaged 141
Screened 273
Tested 91
POCT, 74 RNA
Previously
diagnosed 20
New diagnoses 9Screened 85
Tested 36
POCT, 20 RNA
New diagnoses 19
Figure 3. Screening and treatment done by the intervention each year. Definitions: Screened, individuals approached by the Find & Treat team, not
all of whom needed testing; Tested, individuals who had a test undertaken (either POCT for antibodies or DBS test for RNA, which was sent to a la-
boratory); New diagnoses, found to be RNA positive through testing; Previously diagnosed, identified as already known RNA positive; Engaged,
attended specialist clinic at hospital; Treatment, individuals who have commenced treatment. Numbers of individuals chronically infected were split
by OST/homeless/injecting status and Metavir stage, according to responses in the screening questionnaire, to use as inputs in the mathematical
model.
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mobile screening unit (50% in base case) or a smaller van used by the
Hepatitis C Trust. Further sensitivity analyses tested other assumptions: 0%
and 6% discount rate (3.5% in base case), 100 year time horizon (50 years
in base case), and no HCV care costs for diagnosed individuals in Metavir
stages F0–F3 or F0–F4 (included for all diagnosed individuals in base case).
We also assessed the effect of future (from 2016) increases in engagement
(increased 2-fold) and treatment uptake (increased 2-fold) in the standard-
of-care pathway on the cost-effectiveness of HepFriend.
Lastly, due to ongoing reductions in HCV treatment drug costs, a
threshold analysis was conducted to determine the drug treatment cost
where the mean ICER for HepFriend becomes cost saving.
Results
Costing analysis
The costing analysis estimated the HepFriend intervention costed
£128136 for the year 2017/18 (Table 3): this comprised costs for
the intervention itself, including start-up costs, staff time, test costs,
a proportion of administration, management and finance allocated
to HepFriend, and peer-support costs. Management, administration
and finance support accounted for 36% of these costs. It does not
include the cost of HCV treatment or hospital-related costs. Start-
up costs were relatively small (8% of costs), due to UCLH and
Groundswell already functioning with existing infrastructure. Peer
support for hospital visits accounted for 34% of the total costs of
HepFriend, requiring 2 days a week of peer-worker time: this cost
included the peer worker’s time, materials, related travel and sub-
sistence costs, management and administration support (Table
S3). Using patient numbers from 2017 gives the following costs per
patient: £501 per chronically infected patient diagnosed, £330 per
patient engaged on the treatment pathway and £786 per patient
supported through treatment to SVR.
When calculating costs over 3 years of the intervention, the dir-
ect costs of HepFriend came to £270284. When also including the
cost of DAAs, hospital staff time, equipment for individuals treated
through HepFriend, the cost of HepFriend increased to £3594772.
This did not include cost savings due to prevention benefits or
averted healthcare costs. The costs of HepFriend accounted for
92% of the total incremental costs (Table 4). However, when
compared with the standard-of-care scenario, the HepFriend inter-
vention lowered HCV-related care over the time horizon.
Cost-effectiveness analysis
The 89 treatments undertaken by HepFriend over 3 years resulted
in 51 [95% Credible Interval (CrI) 18–89] infections averted in the
modelled PWID and ex-PWID population [0.10% (95% CrI 0.03%–
0.24%) of all infections] over the time horizon, and 31 (95% CrI 19–
46) disease-related deaths averted; 1.5% (95% CrI 1.0%–2.1%) of
all disease-related deaths. All model runs in the PSA resulted in
positive incremental QALYs, meaning the intervention always
improved health benefits for the population. In terms of cost-
effectiveness, the intervention resulted in an additional 412 QALYs
saved and cost an additional £3.9 million (Table 5; the £3594772
cost of HepFriend plus added costs of HCV treatment for those in-
directly benefiting less a reduction in disease-related healthcare),
giving a mean ICER of £9531 per QALY saved, which is cost-
effective at the WTP threshold of £20000 per QALY. In the PSA,
98% of simulations were below the WTP threshold, and 5% were
cost saving (Figure 4).
Probabilistic sensitivity analysis
The ANCOVA sensitivity analysis showed that uncertainty in the
HCV-related disease care costs contributed most to variability in
Table 3. Costs of HepFriend intervention activities for financial year 2017/18
Activities for financial year 2017/18
Base case
cost (£) 2017/18 Model input
Total cost 128136.70
Total cost of outreach activities (includes staff
time, travel, training and a proportion of
overheads)
in outreach location 16202.85 total cost of diagnosis (1 year),
£61132.55in mobile health unit (includes cap-
ital and recurrent vehicle costs)
24454.91
informing HCV patients of their
status
4999.31
Total cost of tests (includes administrative and
management, staff time, medical supplies and
test costs)
POCT (98 tests for the year) 6942.41
DBS RNA (62 tests for the year) 8533.07
FibroScan (includes staff time and capital cost) 15142.15 total cost of engagement (1 year),
£36338.79! hospital clinic costsEngagement of RNA! patients (follow-up of RNA! tests) 7908.27
Peer support for evaluation visit in hospital peer support costs 13288.37
Peer support for initiating treatment and
subsequent treatment visits 0, 2, 4, 6, 8,
10 weeks
peer support costs 14111.91 total cost of treatment for 1 year
(not including cost of DAA drugs),
£30665.35! hospital clinic costs
! DAAsAdherence support 8289.22
Peer support for post-treatment visits at 12 weeks
and 1 year
peer support costs 8264.22
From UCLH and Groundswell records.
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the incremental costs (Figure S2). Conversely, uncertainty in the
health utilities for successfully treated individuals contributed
most to variability in the incremental QALYs (43% of variation),
while uncertainty in the chronic HCV prevalence in 2016 accounted
for 88% of the variability in the number of infections averted; fewer
infections are averted at higher HCV prevalence.
Sensitivity analyses
At 27% of the list price for sofosbuvir and velpatasvir (£10525 per
course), the intervention becomes cost saving on average, with
38% of all simulations being cost saving (Figure 5). Sensitivity anal-
yses considering effects of changes in the intervention costing
assumptions (two and three times the overhead costs, costs
Table 5. Cost-effectiveness analysis
Total costs (£) Incremental costs (£) Total QALYs Incremental QALYs mean ICER/QALY (£) NMB (£)
Standard of care 1234600679 590434
HepFriend in addition to
standard of care
1238524344 3872848 590846 412 9408 4 360 457
NMB, net monetary benefit.
Table 4. Breakdown of discounted costs (£) over the time horizon of 50 years
Category Comparator mean Intervention mean Mean difference
Healthcare 224884794 223019030 #1865764
HCV treatment of ex-injectors for standard care pathway 52330974 52473116 142142
HCV treatment of PWID for standard care pathway 31578218 33519332 1941114
Testing and engagement for standard care pathway 6039715 6041750 2035
HepFriend intervention costs (includes testing,
engagement and treatment peer support)
0 270284 270284
HCV treatment cost for HepFriend (drug costs only) 0 3324488 3324488
OST provision 919817795 919876344 58549
Total 1234651496 1238524344 3872848
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Figure 4. Cost-effectiveness acceptability curve.
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annualized over 3 or 7 years instead of 5, all screening sessions
using either Find & Treat mobile screening unit or dedicated HCV
mobile van) had very little impact on the cost-effectiveness of the
intervention (Tables S5–S10), as did changes to other intervention
assumptions [all individuals assumed to be current injectors or all
individuals assumed to be new diagnoses; ICER varied from £8348
to £9439 per QALY (Table S11)]. Other sensitivity analyses consid-
ering changes in general assumptions (100 year time horizon, 0%
and 6% discount rate, no disease-related healthcare costs in
F0–F3 or F0–F4 disease stages in undiagnosed individuals) were all
cost-effective at the £20000 per QALY threshold (Figure 6).
Changes in the discount rate had the biggest effect on the ICER
because the intervention accumulates impact over a long time
horizon. Lastly, increasing the standard-of-care treatment rate in
both the comparator and intervention arm slightly improved the
mean ICER to £8853 per QALY, as did increasing the engagement
rate, giving a mean ICER of £8829 per QALY.
Discussion
Main findings
The introduction of a novel care pathway for homeless PWID
based on a mobile testing unit with peer support for HCV case-find-
ing and treatment facilitation is likely to be a highly cost-effective
strategy to improve treatment uptake amongst PWID and home-
less people. Importantly, the intervention is likely to become cost
saving when drug treatment costs decrease below £10525 per
course, as may have already occurred in the UK.37
0
6% discount rate
0% discount rate
100 year time horizon
No cost associated with F0-F3 disease stages
No cost associated with F0-F4 disease stages
2000 4000 6000 8000
Mean ICER (£s per QALY)
10 000 12 000 14 000 16 000 18 000 20 000
Figure 6. General sensitivity analysis. F0 to F4 are Metavir stages of liver disease.
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Strengths and limitations of the study
The key strength of this analysis is the dynamic transmission mod-
elling of the at-risk population, capturing the prevention benefit of
HCV treatment among those who are still injecting. Additionally,
the use of primary cost data and intervention effectiveness data
enabled a robust estimation of the cost-effectiveness under a
range of parameter values and assumptions.
However, there are several limitations to our study. Firstly, we
assumed low treatment uptake rates for the current standard-of-
care comparator. Treatment rates in PWID were low in the pre-
DAA era, with only 10% of individuals ever diagnosed in drug treat-
ment services receiving treatment in a recent study from the UK.17
Uptake rates have improved since then, as used in this analysis,
but they are still relatively low (17% within 2 years of diagnosis).
Because treatment rates are likely to rise, we undertook a sensitiv-
ity analysis that doubled engagement and treatment rates in both
comparator and intervention arms from 2016, which suggested
that the cost-effectiveness of the intervention would improve with
treatment scale-up.
Secondly, for some parameters, we had to use data from other
countries because of a lack of UK data. For example, data on
homeless mortality are sparse and so we used data from a Danish
study to parameterize the model.38 Although it is possible that
these data may not be comparable with the situation in the UK,
uncertainty in this and other parameters did not contribute to the
variability in the cost-effectiveness projections.
Thirdly, the model did not incorporate the additional benefits of
other interventions carried out by the mobile unit, including flu vac-
cination, other bloodborne virus tests and TB screening, and there-
fore our estimates of cost-effectiveness are likely to be
conservative. To account for shared costs, we only allocated a pro-
portion of the mobile screening unit costs to HepFriend in line with
the proportion of time the HCV team used it.
Comparison with other studies
Few studies have evaluated the cost-effectiveness of increased
HCV case-finding amongst high-risk groups including PWID, with
some being based on interventions done prior to the availability of
new DAA treatments.15,39–41 For instance, evaluations from the UK
(DAA)40 and Netherlands (not DAA)15 found that case-finding in
drug treatment centres and prisons could be highly cost-effective
if there is sufficient linkage to treatment. Our analysis adds to
existing studies by considering an intervention that uses outreach
to target homeless individuals and peer workers to aid linkage to
new DAA treatments; no cost-effectiveness analysis has consid-
ered such an intervention before.
Conclusions and implications
Our analysis indicates that using a mobile nurse-led and peer-
based model of outreach for increasing case-finding for HCV and
treatment among PWID is highly cost-effective and could be cost
saving with ongoing reductions in HCV treatment prices. This has
relevance for the UK developing strategies to scale up treatment
for reaching the WHO targets for eliminating HCV as a public health
threat by 2030.42 It suggests that the HepFriend intervention
should be scaled up to improve case-finding and treatment
among vulnerable groups, including homeless individuals, in the
UK. Although UK focused, the findings will also be relevant to other
high-income settings where there is a close connection between
injecting drug use and homelessness. For these countries, this
intervention could have an important role in reaching PWID who
are not in contact with other services. Despite evidence for the
cost-effectiveness of this intervention, future improvements to
this pathway of care could still occur, including the use of point-of-
care RNA tests to remove delays in diagnosis, as well as the initi-
ation and provision of treatment through the outreach van. Both
these strategies could reduce any potential loss to follow-up and
improve the uptake of treatment.
Acknowledgements
We thank Public Health England for the additional analysis of UAM data
for the study.
Funding
This work was supported by the European Commission through its
European Union Third Health Programme (Grant Agreement Number
709844) and National Institute of Health Research (Grant Number
R133221-101).
Transparency declarations
M.H. has received honoraria from Gilead, MSD and Abbvie for presenting
at conferences and expert meetings. Z.W. has received funds for other
research from Janssen. P.V. has received unrestricted research funding
from Gilead and honoraria from Merck. All other authors: none to
declare.
This article forms part of a Supplement sponsored by the HepCare
Europe Project.
Supplementary data
Tables S1 to S11 and Figures S1 to S3 are available as Supplementary
data at JAC Online.
References
1 World Health Organisation. Global Hepatitis Report, 2017. https://www.
who.int/hepatitis/publications/global-hepatitis-report2017/en/.
2 Public Health England.Hepatitis C in theUK2018Report. 2018. http://hcvac
tion.org.uk/sites/default/files/resources/HCV_IN_THE_UK_2018_UK.pdf.
3 Harris RJ, Ramsay M, Hope VD et al. Hepatitis C prevalence in England
remains low and varies by ethnicity: an updated evidence synthesis. Eur J
Public Health2012;22: 187–92.
4 Public Health England. Hepatitis C in England 2018 Report. 2018. https://
webarchive.nationalarchives.gov.uk/20190219232455/https://www.gov.uk/
government/publications/hepatitis-c-in-the-uk.
5 Martin NK, Vickerman P, Foster GR et al. Can antiviral therapy for
hepatitis C reduce the prevalence of HCV among injecting drug user
populations? A modeling analysis of its prevention utility. J Hepatol
2011; 54: 1137–44.
6 Martin NK, Vickerman P, Grebely J et al. Hepatitis C virus treatment for pre-
vention among people who inject drugs: modeling treatment scale-up in the
age of direct-acting antivirals.Hepatology2013;58: 1598–609.
Ward et al.
v14
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/Supplem
ent_5/v5/5645641 by U
niversity of Bristol Library user on 04 D
ecem
ber 2019
7 Martin NK, Vickerman P, Dore GJ et al. Prioritization of HCV treatment in the
direct-acting antiviral era: an economic evaluation. J Hepatol 2016; 65:
17–25.
8 Harris RJ, Martin NK, Rand E et al. New treatments for hepatitis C virus
(HCV): scope for preventing liver disease and HCV transmission in England.
J Viral Hepat2016;23: 631–43.
9 London Joint Working Group. Practical Steps for Elimination of HCV: A
Consensus for London. 2014. http://www.hcvaction.org.uk/resource/prac
tical-steps-eliminating-hepatitis-c-consensus-london.
10 Gupta RK, Lipman M, Story A et al. Active case finding and treatment ad-
herence in risk groups in the tuberculosis pre-elimination era. Int J Tuberc
LungDis2018;22: 479–87.
11 Jit M, Stagg HR, Aldridge RW et al. Dedicated outreach service for hard to
reach patients with tuberculosis in London: observational study and econom-
ic evaluation. BMJ2011;343: d5376.
12 Stagg HR, Surey J, Francis M et al. Improving engagement with health-
care in hepatitis C: a randomised controlled trial of a peer support interven-
tion.BMCMed2019;17: 71.
13 Martin NK, Hickman M, Hutchinson SJ et al. Combination interventions to
prevent HCV transmission among people who inject drugs: modeling the im-
pact of antiviral treatment, needle and syringe programs, and opiate substi-
tution therapy.Clin Infect Dis2013;57: S39–45.
14 Thompson Coon J, Castelnuovo E, Pitt M et al. Case finding for hepa-
titis C in primary care: a cost utility analysis. Fam Pract 2006; 23:
393–406.
15 Helsper CW, Janssen MP, van Essen GA et al. Effectiveness and cost-
effectiveness of nationwide campaigns for awareness and case finding of
hepatitis C targeted at people who inject drugs and the general population in
the Netherlands. Int J Drug Policy2017;47: 117–25.
16 Wright M, Grieve R, Roberts J et al. Health benefits of antiviral therapy for
mild chronic hepatitis C: randomised controlled trial and economic evalu-
ation.Health Technol Assess2006;10: 1–113, iii.
17 Simmons R, Ireland G, Irving W et al. Establishing the cascade of care for
hepatitis C in England—benchmarking to monitor impact of direct acting
antivirals. J Viral Hepat2018;25: 482–90.
18 Harrison GI, Murray K, Gore R et al. The Hepatitis C Awareness Through to
Treatment (HepCATT) study: improving the cascade of care for hepatitis C
virus-infected people who inject drugs in England. Addiction 2019; 114:
1113–22.
19 PSSRU. Unit Costs of Health & Social Care 2013. 2013. Report No.:
9781902671871. https://www.pssru.ac.uk/project-pages/unit-costs/.
20 Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following
acute hepatitis C infection: a systematic review of longitudinal studies. J Viral
Hepat2006;13: 34–41.
21 Hepatitis C: Operational Delivery Network Profile Tool. PHE Publishing,
2018. https://www.gov.uk/government/publications/hepatitis-c-commission
ing-template-for-estimating-disease-prevalence.
22 Public Health England. People Who Inject Drugs: HIV and Viral Hepatitis
Unlinked Anonymous Monitoring Survey Tables (Pyschoactive): 2016 Update.
2016. https://www.gov.uk/government/uploads/system/uploads/at
tachment_data/file/537598/UAM_Survey_of_PWID_2016_data_tables_
with_2015_data_FINAL.pdf.
23 Platt L, Minozzi S, Reed J et al. Needle and syringe programmes and opi-
oid substitution therapy for preventing HCV transmission among people who
inject drugs: findings from a Cochrane Review and meta-analysis. Addiction
2018;113: 545–63.
24 Platt L, Sweeney S, Ward Z et al. Assessing the impact and cost-
effectiveness of needle/syringe provision on hepatitis C transmission among
people who inject drugs in the United Kingdom: analysis of pooled datasets
and economic modelling. Public Health Res2017;5: 1–118.
25 Information Services Division Scotland. Injecting Equipment
Provision in Scotland Survey 2013/14. 2015. https://www.isdscotland.
org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2015-06-23/
2015-06-23-IEP-Report.pdf.
26 Grebely J, Dalgard O, Conway B et al. Sofosbuvir and velpatasvir for hepa-
titis C virus infection in people with recent injection drug use (SIMPLIFY): an
open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol
Hepatol2018;3: 153–61.
27 Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient
elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in
chronic hepatitis C.Gastroenterol2005;128: 343–50.
28 Smith DJ, Combellick J, Jordan AE et al. Hepatitis C virus (HCV) disease
progression in people who inject drugs (PWID): a systematic review and
meta-analysis. Int J Drug Policy2015;26: 911–21.
29 van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained
virological response and all-cause mortality among patients with chronic
hepatitis C and advanced hepatic fibrosis. JAMA2012;308: 2584–93.
30 Morgan RL, Baack B, Smith BD et al. Eradication of hepatitis C virus infec-
tion and the development of hepatocellular carcinoma: a meta-analysis of
observational studies.Ann InternMed2013;158: 329–37.
31 Shepherd J, Jones J, Hartwell D et al. Interferon alpha (pegylated and
non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a
systematic review and economic evaluation.Health Technol Assess 2007; 11:
1–205, iii.
32 Ioannou GN, Feld JJ. What are the benefits of a sustained virologic
response to direct-acting antiviral therapy for hepatitis C virus infection?
Gastroenterol2019;156: 446–60.e2.
33 McDonald SA, Hutchinson SJ, Palmateer NE et al. Decrease in health-
related quality of life associated with awareness of hepatitis C virus
infection among people who inject drugs in Scotland. J Hepatol 2013;
58: 460–6.
34 Lewer D, Aldridge RW, Menezes D et al. Health-related quality of life and
prevalence of six chronic diseases in homeless and housed people: a cross-
sectional study in London and Birmingham, England. BMJ Open 2019; 9:
e025192.
35 NICE. Guide to the Methods of Technology Appraisal 2013. 2013. www.
nice.org.uk/process/pmg9.
36 Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic
Evaluation. Oxford University Press, 2006.
37 Douglass CH, Pedrana A, Lazarus JV et al. Pathways to ensure universal
and affordable access to hepatitis C treatment. BMCMed2018;16: 175.
38 Nielsen SF, Hjorthoj CR, Erlangsen A et al. Psychiatric disorders and
mortality among people in homeless shelters in Denmark: a nationwide
register-based cohort study. Lancet2011;377: 2205–14.
39 Martin NK, Hickman M, Miners A et al. Cost-effectiveness of HCV case-
finding for people who inject drugs via dried blood spot testing in specialist
addiction services and prisons. BMJOpen2013;3: pii=e003153.
40 Martin NK, Vickerman P, Brew IF et al. Is increased hepatitis C virus case-
finding combined with current or 8-week to 12-week direct-acting antiviral
therapy cost-effective in UK prisons? A prevention benefit analysis.
Hepatology2016;63: 1796–808.
41 Morgan JR, Servidone M, Easterbrook P et al. Economic evaluation of HCV
testing approaches in low and middle income countries. BMC Infect Dis 2017;
17: 697.
42 World Health Organization. Combating Hepatitis B and C to Reach
Elimination by 2030. 2016. http://apps.who.int/iris/bitstream/10665/206453/
1/WHO_HIV_2016.04_eng.pdf.
43 Joint Formulary Committee. British National Formulary. BNF Publications,
2014.
Cost-effectiveness of a London HCV intervention JAC
v15
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/Supplem
ent_5/v5/5645641 by U
niversity of Bristol Library user on 04 D
ecem
ber 2019
44 Field Epidemiology Service South East and London. Hepatitis C
Epidemiology in London: 2015Data. 2017.
45 Sweeting M, De Angelis D, Ades A et al. Estimating the prevalence of ex-
injecting drug use in the population. StatMethodsMedRes2009;18: 381–95.
46 Kemp PA, Neale J, Robertson M. Homelessness among problem drug
users: prevalence, risk factors and trigger events. Health Soc Care Community
2006;14: 319–28.
47 Cornish R, Macleod J, Strang J et al. Risk of death during and after opiate
substitution treatment in primary care: prospective observational study in UK
General Practice Research Database.BMJ2010;341: c5475.
48 Aldridge RW, Story A, Hwang SW et al. Morbidity and mortality in home-
less individuals, prisoners, sex workers, and individuals with substance use
disorders in high-income countries: a systematic review and meta-analysis.
Lancet2018;391: 241–50.
Ward et al.
v16
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/Supplem
ent_5/v5/5645641 by U
niversity of Bristol Library user on 04 D
ecem
ber 2019
